Globus Medical holds the cleaner structural position, with growth as the main driver and valuation adding further support. Genmab A/S does not offset that deficit through any equally strong structural edge elsewhere. The market setup broadly confirms the structural lead — Globus Medical holds the more constructive position. That puts structure and market broadly in agreement — Globus Medical's lead looks more confirmed than conflicted.
The comparison is based on similar long-term financial trajectories, not sector labels.
Most of the separation is still concentrated in growth. Globus Medical, Inc. leads by 24 points on the overall comparison score.
This comparison is anchored in long-term financial trajectory similarity within the selected peer universe.
The pair shares a valid long-term profile match, but the trajectories are not especially close.
Most of the shared profile comes through recent revenue growth and margin trend.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
The largest gaps do not all point in the same direction.
Left means cheaper relative valuation. Higher means stronger structure.
Globus Medical, Inc. looks stronger on relative valuation, while the broader price setup remains mixed.
Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.
Revenue growth reinforces the category-level growth lead.
Genmab A/S still carries lower volatility exposure — that difference is real enough to prevent the comparison from becoming one-sided.
Growth is the clearest driver, and valuation also supports Globus Medical, Inc.'s broader structural position.
Break down the GMAB.CO vs GMED comparison across all dimensions with the full interactive tool.
Explore how GMAB.CO and GMED each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.